Impact of Non-CF Bronchiectasis on Medicare Utilization
Recent research into non-cystic fibrosis bronchiectasis (non-CF BE) points to a significant impact on healthcare utilization among Medicare beneficiaries, particularly older adults and females.
Non-CF BE, a lesser-known respiratory condition, is drawing attention because it necessitates substantial healthcare services, particularly among aging populations. According to a thorough cohort analysis using Medicare fee-for-service (FFS) claims and Medicare Advantage (MA) encounter records, this condition requires targeted care strategies due to its implications for healthcare resource use and associated costs.
Study Details and Methodology
The extensive study utilized complete U.S. Medicare data from 2016 to 2023 to analyze healthcare utilization among beneficiaries with non-CF BE. It also examined the prevalence of this condition in 2023, categorized by various demographics and geographic locations. The study criteria required continuous enrollment in Medicare Part A/B (FFS), Part C (MA), and Part D for a year before diagnosis, excluding individuals with conditions like prior lung transplants or cystic fibrosis. Incident cases were identified using specific ICD-10-CM codes.
Key Findings
From 2017 to 2022, 600,841 beneficiaries were newly diagnosed with non-CF BE, with patients evenly distributed between FFS and MA plans. The average age of those diagnosed was 75.9 years, with a majority being female and over 65. Inpatient hospitalizations and emergency department visits were notably high, indicating significant healthcare resource use.
| Year | Patients Diagnosed | Inpatient Visits (%) |
|---|---|---|
| 2017-2022 | 600,841 | 66.2% (FFS), 61.2% (MA) |
Financial Implications and Healthcare Costs
The financial burden of non-CF BE is substantial. Data revealed that average monthly healthcare expenditure for FFS beneficiaries during the follow-up period was $8,998 in 2023 dollars. This expenditure primarily stems from inpatient services and necessary outpatient medications, indicating a pressing need for more cost-effective care solutions.
Prevalence and Trends
The second part of the study, conducted in 2023, estimated a prevalence rate of 1,004 cases per 100,000 person-years among a Medicare population over 53 million. Higher prevalence rates were observed among older and female beneficiaries, highlighting a demographic trend that may require more specialized healthcare interventions to manage growing cases efficiently.
Implications for Insurance Professionals
For insurance professionals, understanding the nuances of non-CF BE is crucial given the heightened healthcare needs and financial burdens associated with the condition. Efforts to develop enhanced care models that reduce the strain on acute healthcare services, while optimizing coordinated care strategies, are necessary. Such initiatives could help mitigate costs and improve outcomes for affected beneficiaries.
These findings will be presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona. This scheduled presentation underscores the ongoing dialogue about integrating improved care strategies for managing non-CF BE within the Medicare framework.